Cite

HARVARD Citation

    Davis, S. et al. (2020). Low‐dose ibrutinib in the treatment of refractory pure red cell aplasia in chronic lymphocytic leukaemia. Internal medicine journal. 50 (8), pp. 1013-1015. [Online]. 
  
Back to record